Collaborative
relationships
Major Research and Development Interactions
Pharmagenesis,
Inc. recognizes scientific collaborations as an essential part of its Research and Development and commercialization strategies.
New collaborations are currently being developed. Several collaborative agreements were
previously established.
Stanford
University Medical School, Stanford, CA
Pharmagenesis,
Inc. has two sponsored research agreements with Stanford involving the anti-cancer lead,
PG490. One Principle Investigator is seeking
to determine the molecular target of this agent and the other is focusing on describing
its in vitro and in vivo anti-cancer mechanism of action.
Duke
University, Durham, NC
An
investigator at Duke is examining effects of PG490-88 on graft-vs.-host disease. This investigator is also acting as a consultant
to Pharmagenesis, Inc. for the PG2-2000 development program.
H.
Lee Moffitt Cancer Center and Research Institute, University of South Florida
Pharmagenesis, Inc. has one sponsored research agreement in place with the Moffitt Center. The objective is to evaluate PG2-2000 as a
modulator of hematopoiesis.
Shanxi
Institute of Chinese Materia Medica, Taiyuan, Shanxi province, PRC
The
institute collaborated with Pharmagenesis, Inc. on the development of PG2.
Shanghai
Institute of Materia Medica, Shanghai, PRC
They supply Pharmagenesis, Inc. with compounds.
University
of North Carolina, Chapel Hill, NC
Pharmagenesis, Inc. has a research collaboration to obtain additional compounds and
derivatives from the same TCM plants that produce PG490, PG2 and PG2-2000.
Tri-Service
General Hospital, Taipei, Taiwan
There
is a collaboration on treating autoimmune diseases with PG27.
Fujian
Shanyang Development Co., Ltd. and Fujian Agricultural University, Fujian, PRC
Pharmagenesis, Inc. is collaborating with them for GAP cultivation of TCM plants.
Lijiang
Pharmaceutical Co., Ltd.
There is a collaboration on TCM plant biomass collection and crude extraction.
Research
Interactions
The
majority of earlier Pharmagenesis' collaborators were academic researchers from Taiwan,
the PRC and the US.
Taiwan
The
previous research collaborators in Taiwan belong to:
Taibei
Medical University, Taibei, Taiwan
National
Chung Kung University, Tainan, Taiwan
Kaoshiung
Medical University, Kaoshiung, Taiwan
Peoples
Republic of China
The
academicians in the PRC were at:
Shanghai
Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
China
Institute of Traditional Chinese Medicine, Beijing, China
Peking
University Medical School, Beijing, China
United
Medical University, Beijing, China
United
States
The
major investigators in the U.S. were at:
Stanford
University Medical School, Stanford, CA
University
of North Carolina at Chapel Hill
H.
Lee Moffitt Cancer Center and Research Institute, University of South Florida
|